Presentation on theme: "Biosafety Capacity Building Initiatives in India"— Presentation transcript:
1Biosafety Capacity Building Initiatives in India Dr. Manoranjan HotaMinistry of Environment an ForestsNew Delhi
2GMOs are inherently different and carry special risks and hazards, and hence need to be regulated nationally so also internationally.Countries always has the sovereign right to regulate GMOs/LMOs and their products at the national level.
3Are we producing transgenic organisms for research? 1. What are we intending to do with any genetically modified organisms in the country?Are we producing transgenic organisms for research?Are we producing transgenic organisms for commercial use? If not, do you intend to produce transgenic organisms?Do we intend to import or are you already importing transgenic organisms?Do we intend to export or are you already exporting transgenic organisms?2. What is the current state of the biotechnology industry?3. Are any research institutes working with, or manufacturing, living modified organisms?4. What are the national priorities in relation to LMOs?5. Are there existing laws, legal and institutional/administrative systems, local, national and international obligations related to Biosafety, even in a peripheral manner?
4What government departments (including local government) may have jurisdiction in relation to LMOs?What is the legal system, knowing that a legal system maycontain one or more of the following: common law, civil law,mixed system, federal laws and state laws? What are the levels of competence held by different bodiesWhere these may cover areas such as: laws, bylaws, guidelines,regulation, guidance, codes of practice administered at federal,state or regional level?What are the possible range of responsibilities and overlapbetween different agencies and departments, led, as well as thegaps where there is no, or inadequate, coverage?What are the current or planned environmental laws that couldimpact on health, trade, agriculture, food, feed, workerprotection, etc?
6Capacity: individual, institutional and systemic levels In a global context, “capacity” refers to the ability of individuals and institutions to make and implement decisions and perform functions in an effective, efficient and sustainable manner.At the individual level, capacity building refers to the process of changing attitudes and behaviors - imparting knowledge and developing skills while maximizing the benefits of participation, knowledge exchange and ownership.
7In the field of biosafety, the kinds of capacity at this level would refer to human expertise in the legal, scientific or technical areas, for example, in risk assessment and risk management.Capacity building also refers to increased awareness of biosafety issues.At the institutional level it focuses on the overall organisational performance and functioning capabilities, as well as the ability of an organisation to adapt to change. It aims to develop the institution as a total system, including individuals, groups and the organisation itself.
8International Obligations In Agenda 21, as well as in the Convention on Biological Diversity, Governments committed for international co-operation on biotechnology and relevant safety aspects viz. sharing experience, capacity building, and international agreement on principles for safety in biotechnology or biosafety.Article 22 of the Cartagena Protocol on Biosafety “Capacity-Building” requires the Parties shall cooperate in the development and/or strengthening of human resources and institutional capacities in biosafety, including biotechnology to the extent that it is required for biosafety, for the purpose of the effective implementation of this Protocol.
9Biosafety & LMMCColombia has placed a high priority on developing a biosafety framework and coordination of the implementation of the Biosafety Clearing House (BCH). The project, inter alia, focused on to develop national capacities in biosafety.Malaysia has established a a Genetic Modification Advisory Committee (GMAC) to ensure safety in the use, handling and transfer of GMOs, and to advise the Government about genetic modification technology.Philippines, established a National Biosafety Committee which marked the start of a regulatory regime to ensure biosafety. Philippines developed guidelines for the planned release of GMOs.
10An analysis of the existing biosafety capacity building information indicates A large number of countries have no national biosafety frameworks regulating LMOs;Existing national biosafety regulations address only activities relating to the domestic handling and use of LMOs (no address for CPB);The biosafety frameworks should be credible, flexible, transparent, predictable, focused on clear objectives, adaptable to different socio-economic and cultural conditions, and cost-effective.
11Some areas identified in the Protocol requiring capacity building/strengthening in developing countries, including IndiaStrengthening of regulatory frameworkTraining needs and human resource developmentPublic awarenessRisk assessment and managementTrans-boundary movement of LMOsHandling transport packaging and identificationInformation sharing
13Development General (all 3 stages) Choices Processes Tools Why are you inviting people to participate?What do citizens know,what are they concernedabout?Clarifying purposes of a process and how people’s inputs will be used.Engaging with areas of public concern (rather than assuming what people needto know).Information-gathering surveys.Relevant, targeted information distributed in appropriate media,formats and styles.Stakeholder forums that are accessible and widely advertised.Development• Who should participate inthe design process?• Are people enabled toparticipate?• Identify key stakeholders,going beyond groups thatidentify themselves asStakeholders.• Ensuring adequate legalframeworks (rights toinformation, access todecision-making) are in place.• Ensuring people aresufficiently informed about theissues to engage meaningfullywith the process• Local and regional consultations to discussissues and solicit views.• Laws enabling publicparticipation and access toinformation.• Decision trails showing how views will be carried forward, follow-up explanations about howand why inputs have or have not been used.
14Implementation Monitoring • How far to include people in decisions about:• The roles, duties andpowers of responsibleagencies• Mechanisms of reporting,public scrutiny andaccountability.• The location and design ofbiosafety trials• Openness about applicationsfor biosafety review andcommercialisation.• Openness about the purpose,location and design ofbiosafety trials.• Opportunities for publiccomment.• Using risk analogies withwhich people are be morefamiliar.• Public registers ofapplications under review,with opportunities forpublic comment andobligations to respond topublic comments.Monitoring• How to involve people inreflection and evaluation ofthe adequacy of theexisting NBF framework?• Sharing and explainingfindings of trials, creatingfeedback mechanisms andprocedures for acting uponthese• Non-specialist involvementin advisory and reviewcommittees• Local level evaluationspublic comment.• Constructing mechanismsfor ongoing participatory(re)evaluation of thebiosafety system.
15Institutional structures for developing biosafety framework National Executive Agency need to have:Strong technical & human resource capabilitiesStrong political mandateCoordinating capabilitiesStrong commitmentSustainability
16Government Commitment for Biosafety Notified Rules in 1989 for activities relating to research, development and use of Genetically Modified Organisms (GMOs) and their products.MoEF is the focal point for all biodiversity related matters including biosafety; andRatified the Cartagena Protocol in January, 2003.
17Baseline Capacity and Identified Gaps India, being,one of the 12 mega-diversity countries, attaches great importance to the biotechnology and biosafety.After entry into the force of the CP, possibility of increased movement of the LMOs. Therefore, there is a need for enhancing the capacity in the context of the CP.
18Indian R & D institutions has expertise for conducting research in this area. However,they need to be strengthened to meet the challenges that are emerging with the rapidly changing biosafety scenario.Information sharing protocols and additional data capacity are needed to be enhanced to keep pace with the expected increase in trans-boundary movement of LMOs.
19Capacity enhancement in assessment of risks associated with LMOs and an understanding of the transgenic sequence.Increasing awareness building programmes for participation of all stakeholder groups play an important role.
21Indian Regulatory Mechanism for GM Crops Applicant / InvestigatorsTo NoteTo ApproveTo recommend &Seek approval of RCGMR & D FundingIBSCTo NoteT o Approve / recommend Permits.To monitor trialsTo recommend course of actionApplic/Investi toreport periodicallyRCGMConveys its decision toapplicant / investigatorGEACApplicant /Investigator toconduct trialsLarge scale trials conducted/Commercial release
22Synergy between CPB EPA Linkage of National Policy and legislation need to be dovetailed to the International Agreements.1989 Rules & the CPBCapacity Developments need to be catalyzed
23Essence of the Protocol This Protocol shall apply to the trans-boundary movement, transit, handling and use of all living modified organisms that may have adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health.
24Areas of Capacity Developments AIARARMRCPublic awarenessBCHImplementation of Regulations
26Cartagena Protocol on Biosafety (CPB) Article 22 CAPACITY-BUILDING:Development and/or strengthening of human resources and institutional capacities in biosafety, including biotechnology to the extent that it is required for biosafety.
27CPB…. Article : 23 : PUBLIC AWARENESS AND PARTICIPATION Article: 26 : SOCIO-ECONOMIC CONSIDERATIONSArticle 27 : LIABILITY AND REDRESS
28CPB…. Art.: 15 Risk Assessment Art.: 16 Risk Management Art.: 18 Handling, Transport, Packaging and IdentificationArt.: 20 Information Sharing and the Biosafety Clearing - House (BCH)
29Risk Assessment Most critical component of biosafety implementation. Used for assessment of environmental risk and the reality.Estimate the likelihood of these adverse effects being occurred.Consequences of the risk should the identified.Consider appropriate risk-management strategies
30Article 20: a Biosafety Clearing-House is to: (a) Facilitate the exchange of scientific, technical, environmental and legal information on, and experience with, living modified organisms; and(b) Assist Parties to implement the Protocol, taking into account the special needs of developing and least developing country Parties,
33Institutional strengthening Develop multidisciplinary expertise to improve core competence within institutions.Strengthening laboratories with sophisticated equipment.Training to improve skills in handling sophisticated equipments.Directed research.
34Risk assessment capacities Develop protocols and guidelines for various scenarios.Development of standards/limits.Training to carryout risk assessment and risk management.
35Information sharing and data base management Networking with various institutes and agencies.Development of databases.Web management for information dissemination to various stakeholders.
36Involvement of stakeholders Societal acceptance is the key element for successful implementation of various polices and adaptation of technologies.Introduction of public consultation mechanism.Awareness programs.
37Projects on Capacity Building in Biosafety GEF-World Bank Project.FAO Regional Capacity Building Project.
38GEF-World Bank Project: Objectives Capacity building enhancement for effective coordination between the responsible agencies to assess and manage risks associated with the trans-boundary movement of LMOs.Knowledge and methodologies on Biosafety will be shared and transferred to the state agencies through training programmes.
39strengthen institutional capacity for coordination and decision making across ministries, specialized agencies and in state government in areas related to biosafety and the CP.strengthen technical capacity to assess, manage and monitor risks associated with biosafety through the provision of training for core capacity development in relevant stakeholder ministries, specialized agencies and in state governments.
40Establish biosafety database system and Biosafety Clearing House Mechanism. Support centers of excellence and a network for research, risk assessment, and monitoring.
41Improving capacity for risk evaluation and management Develop field capacity to monitor possible gene flow between introduced LMOs and semi domestic and wild relatives.Training for implementation of biosafety measures and to identify potential gene flow, as well the effect on non-target species.Training on socio-economic impact assessment of LMOs.
42form the first part of a long-term national effort to consolidate the Biosafety framework. Each of the proposed activities addresses possible gaps or barriers.Designed to strengthen not only the capabilities of the focal point to the CP, but also of key Ministries, agencies and scientific research institutions.
43Physical mile stonesFour institutions are being strengthened in terms of institutional and technical capacities to assess, manage and monitor risks associated with biosafety
492. FAO Regional Capacity Building Project on Biosafety of GM Crops Regional Consultation for Standardization of procedures for risk assessment / management (double verification and GMO detection).Public awareness of GMOs including material and methodologies for effective out reach.Establishment of Asian Bionet.
50It is not too late, nor so the risk of Biosafety vis-à-vis the Management; But, if the risks exceeds the Management of the Techno-Socio-Political will then…….